What is Impel Pharmaceuticals?
Impel Pharmaceuticals Inc. is a commercial-stage pharmaceutical company based in Seattle, Washington. The company is dedicated to the development of first-in-class intranasal drug treatments targeting a range of central nervous system (CNS) disorders. By focusing on innovative drug delivery mechanisms, Impel aims to provide more effective and patient-friendly therapeutic options for complex neurological conditions. The company's strategic focus on intranasal delivery represents a novel approach to treating CNS disorders, potentially bypassing traditional administration challenges and improving drug efficacy.
How much funding has Impel Pharmaceuticals raised?
Impel Pharmaceuticals has raised a total of $346.6M across 7 funding rounds:
Series B
$12M
Debt
$1.1M
Series C
$36M
Series D
$67.5M
Stock Offering
$80M
Debt
$50M
Other Financing Round
$100M
Series B (2015): $12M with participation from 3M New Ventures
Debt (2016): $1.1M, investors not publicly disclosed
Series C (2016): $36M supported by Vivo Capital, venBIO, and 5AM Ventures
Series D (2018): $67.5M featuring Vivo Capital, KKR & Co. (Kohlberg Kravis Roberts & Co.), venBio, 5AM Ventures, and Norwest Venture Partners
Stock Issuance/Offering (2021): $80M, investors not publicly disclosed
Debt (2021): $50M with participation from Silicon Valley Bank
Other Financing Round (2022): $100M led by Oaktree Capital Management
Key Investors in Impel Pharmaceuticals
Oaktree Capital Management
Oaktree Capital Management is a leading global investment management firm specializing in alternative investments, known for its opportunistic, value-oriented, and risk-controlled approach across credit, equity, and real estate markets. The firm partners with clients worldwide to identify investment opportunities that balance potential returns with disciplined risk management.
Silicon Valley Bank
SVB Financial Group offers a comprehensive suite of financial services including commercial and private banking, asset management, and investment services. Founded in 1983 and headquartered in Santa Clara, California, SVB is a key financial partner for technology and innovation-driven companies.
Vivo Capital
Vivo Capital, founded in 1996 and headquartered in Palo Alto, California, is a global healthcare investment firm with a focus on private and public equity, as well as venture capital investments within the healthcare sector.
What's next for Impel Pharmaceuticals?
With the recent infusion of major strategic capital, Impel Pharmaceuticals is poised for significant advancements in its drug development pipeline and commercialization efforts. The substantial enterprise-level funding indicates a strong investor confidence in the company's technology and market strategy. This backing is anticipated to fuel further research and development, clinical trials, and the scaling of manufacturing capabilities. Impel's focus on intranasal drug delivery for CNS disorders positions it to address critical unmet medical needs, suggesting a trajectory towards market entry and broader therapeutic impact.
See full Impel Pharmaceuticals company page
